Stock D4S DAIICHI SANKYO CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Daiichi Sankyo Co., Ltd. Deutsche Boerse AG

Equities

D4S

JP3475350009

Real-time Estimate Tradegate
Other stock markets
 09:09:24 2024-04-18 am EDT 		5-day change 1st Jan Change
27.6 EUR +1.49% Intraday chart for Daiichi Sankyo Co., Ltd. -0.15% +11.28%
Apr. 10 Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark MT
Apr. 08 AstraZeneca's Enhertu Receives FDA Approval for HER2-Positive Solid Tumor Indication MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark
MT
AstraZeneca's Enhertu Receives FDA Approval for HER2-Positive Solid Tumor Indication
MT
Astrazeneca - Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-Positive solid tumours
AQ
AstraZeneca, Daiichi Sankyo Secure Accelerated US FDA Clearance for Cancer Treatment Enhertu
MT
AstraZeneca: US approval extended for Enhertu
CF
AstraZeneca hails neurological data for Ultomiris, Soliris
AN
AstraZeneca, Daiichi Sankyo's Solid Tumor Drug Wins US FDA's Accelerated Approval
MT
Astra hails neurology data; CVS flags cyberattack
AN
AstraZeneca's, Daiichi's Enhertu receives US FDA approval
AN
AstraZeneca Wins US Approval for Solid Tumor Treatment
MT
Daiichi Sankyo : ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors (375.5KB
PU
Astrazeneca and Daiichi Sankyo's ENHERTU Receives Approval in US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients with Metastatic HER2-Positive Solid Tumors
CI
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
RE
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer
MT
Daiichi Sankyo - Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
AQ
Merck: 1st patient in raludotatug study
CF
Daiichi Sankyo : REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer(193.7KB
PU
Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer
CI
AstraZeneca, Daiichi make US progress with licence approvals
AN
FTSE 100 Ends Lower; UK Manufacturing Sector Escapes Contraction
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4568 Stock
  4. D4S Stock
  5. News Daiichi Sankyo Co., Ltd.